Benign Prostatic Hyperplasia - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 128 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H2 2016, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 5, 6, 1, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.Benign Prostatic Hyperplasia.

Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
- The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Benign Prostatic Hyperplasia Overview 10
Therapeutics Development 11
Pipeline Products for Benign Prostatic Hyperplasia - Overview 11
Pipeline Products for Benign Prostatic Hyperplasia - Comparative Analysis 12
Benign Prostatic Hyperplasia - Therapeutics under Development by Companies 13
Benign Prostatic Hyperplasia - Therapeutics under Investigation by Universities/Institutes 15
Benign Prostatic Hyperplasia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Benign Prostatic Hyperplasia - Products under Development by Companies 20
Benign Prostatic Hyperplasia - Products under Investigation by Universities/Institutes 22
Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development 23
Addex Therapeutics Ltd 23
AndroScience Corporation 24
Aphios Corporation 25
BCWorld Pharm Co. Ltd. 26
Biolab Farmaceutica Ltda 27
Chong Kun Dang Pharmaceutical Corp. 28
Dongkook Pharmaceutical Co., Ltd. 29
Hanmi Pharmaceuticals, Co. Ltd. 30
Health Ever Bio-Tech Co., Ltd. 31
Jeil Pharmaceutical Co., Ltd. 32
Kaken Pharmaceutical Co., Ltd. 33
MEI Pharma, Inc. 34
Meiji Seika Pharma Co., Ltd. 35
Mezzion Pharma Co. Ltd. 36
Monosol Rx LLC 37
Nymox Pharmaceutical Corporation 38
Ogeda SA 39
Ono Pharmaceutical Co., Ltd. 40
SK Chemicals Co., Ltd. 41
SOM Biotech SL 42
Sophiris Bio, Inc. 43
Vantia Therapeutics 44
XuanZhu Pharma Co Ltd 45
Yungjin Pharm. Co., Ltd. 46
Benign Prostatic Hyperplasia - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Target 49
Assessment by Mechanism of Action 51
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
(dutasteride + tadalafil) - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
(solifenacin succinate + tamsulosin hydrochloride) - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
(tadalafil + tamsulosin hydrochloride) - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
ADX-68692 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
ASC-JM.X2 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
AUS-131 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
BCWPE-004 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
BL-214 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
ESN-364 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
fadanafil - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
fedovapagon - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
fexapotide triflutate - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
HCP-1303 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
HIP-1402 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
KKM-1202 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
L-1AD3 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
MCS-2 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
NCE-403 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
ONO-8430506 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
S-40542 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
SOM-2391 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
SOM-2393 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Sperol - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
tadalafil - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
talaporfin sodium - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
tamsulosin hydrochloride CR - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
tamsulosin hydrochloride DR - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
tamsulosin hydrochloride SR - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
tertomotide - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
topsalysin - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
udenafil - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
YBH-1603 - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
YOB-1604 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
Benign Prostatic Hyperplasia - Dormant Projects 113
Benign Prostatic Hyperplasia - Discontinued Products 116
Benign Prostatic Hyperplasia - Product Development Milestones 117
Featured News & Press Releases 117
Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68692 117
May 05, 2016: Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting 118
Apr 01, 2015: Nymox Announces Phase 3 BPH Studies 118
Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 118
Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints 119
Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 119
Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH 120
Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study 121
Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207 121
Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug 122
May 08, 2014: Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH 123
Nov 11, 2013: Nymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH 124
Oct 28, 2013: Sophiris Announces First Patients Dosed in the PLUS-1 Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 125
Aug 22, 2013: Nymox Reports Positive Results of Safety Monitoring Committee Review of NX02-0018 Phase 3 Trial 125
Jul 11, 2013: Nymox Reports Positive Safety Monitoring Committee Results for Pivotal NX02-0017 Phase 3 Trial 126
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 127
Disclaimer 128

List of Tables

Number of Products under Development for Benign Prostatic Hyperplasia, H2 2016 11
Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Comparative Analysis by Unknown Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Development by Companies, H2 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2016 22
Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H2 2016 23
Benign Prostatic Hyperplasia - Pipeline by AndroScience Corporation, H2 2016 24
Benign Prostatic Hyperplasia - Pipeline by Aphios Corporation, H2 2016 25
Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co. Ltd., H2 2016 26
Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H2 2016 27
Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 28
Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2016 29
Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 30
Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co., Ltd., H2 2016 31
Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 32
Benign Prostatic Hyperplasia - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016 33
Benign Prostatic Hyperplasia - Pipeline by MEI Pharma, Inc., H2 2016 34
Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2016 35
Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co. Ltd., H2 2016 36
Benign Prostatic Hyperplasia - Pipeline by Monosol Rx LLC, H2 2016 37
Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corporation, H2 2016 38
Benign Prostatic Hyperplasia - Pipeline by Ogeda SA, H2 2016 39
Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 40
Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co., Ltd., H2 2016 41
Benign Prostatic Hyperplasia - Pipeline by SOM Biotech SL, H2 2016 42
Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio, Inc., H2 2016 43
Benign Prostatic Hyperplasia - Pipeline by Vantia Therapeutics, H2 2016 44
Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H2 2016 45
Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 46
Assessment by Monotherapy Products, H2 2016 47
Assessment by Combination Products, H2 2016 48
Number of Products by Stage and Target, H2 2016 50
Number of Products by Stage and Mechanism of Action, H2 2016 52
Number of Products by Stage and Route of Administration, H2 2016 54
Number of Products by Stage and Molecule Type, H2 2016 56
Benign Prostatic Hyperplasia - Dormant Projects, H2 2016 113
Benign Prostatic Hyperplasia - Dormant Projects (Contd..1), H2 2016 114
Benign Prostatic Hyperplasia - Dormant Projects (Contd..2), H2 2016 115
Benign Prostatic Hyperplasia - Discontinued Products, H2 2016 116